Xiamen-based Kingdomway, also the parent firm of dietary supplement brand Doctor’s Best, said net profit had plummeted 67 per cent last year, largely due to a drop in the selling price of vitamin A and coenzyme-Q10 – two of its largest raw material businesses.
Doctor’s Best will be expanding its nicotinamide mononucleotide (NMN) product offering in China this year as product sales hit RMB$64m (US$9.8m) in 2020.
China’s increasing interest in nicotinamide mononucleotide (NMN), colloquially known as ‘the longevity pill’ in the country, has push sales to a new high for brands from the US brand Doctor’s Best, New Zealand’s EZZ, and Japan’s NADaltus.
A nicotinamide mononucleotide (NMN) supplement made by US supplement firm Doctor’s Best had hit the US$1m sales in the first 10 days of its launch in China.
